- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | REVELATION BIOSCIENCES, INC. - S-8, Securities to be offered to employees in employee benefit plans | - | SEC Filings | ||
| 06.04. | Revelation Biosciences forms advisory board for AKI trial | 3 | Investing.com | ||
| 06.04. | Revelation Biosciences, Inc.: Revelation Biosciences Announces Formation of Acute Kidney Injury Advisory Board | 290 | ACCESS Newswire | SAN DIEGO, CA / ACCESS Newswire / April 6, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company developing innovative solutions to... ► Artikel lesen | |
| 30.03. | Revelation Biosciences, Inc.: Revelation Biosciences Inc. Presents Additional Positive Data from Prime Clinical Study | 143 | ACCESS Newswire | - A majority of CKD patients present with cellular inflammation and immunoparalysis predose --Gemini durably normalizes cellular inflammation and restores immunocompetence - SAN DIEGO, CA / ACCESS Newswire... ► Artikel lesen | |
| 24.03. | Revelation Biosciences, Inc.: REMINDER: Revelation Biosciences to Host Fireside Chat at 38th Annual Roth Conference | 156 | ACCESS Newswire | SAN DIEGO, CA / ACCESS Newswire / March 24, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company focused on rebalancing inflammation... ► Artikel lesen | |
| 19.03. | REVELATION BIOSCIENCES, INC. - 8-K, Current Report | 3 | SEC Filings | ||
| REVELATION BIOSCIENCES Aktie jetzt für 0€ handeln | |||||
| 19.03. | Revelation Biosciences, Inc.: Revelation Biosciences to Host Fireside Chat at 38th Annual Roth Conference | 304 | ACCESS Newswire | SAN DIEGO, CA / ACCESS Newswire / March 19, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company focused on rebalancing inflammation... ► Artikel lesen | |
| 27.02. | Revelation Biosciences reports FY results | 2 | Seeking Alpha | ||
| 26.02. | Revelation Biosciences, Inc. Announces Financial Results For the Three and Twelve Months Ended December 31, 2025 | 360 | ACCESS Newswire | SAN DIEGO, CA / ACCESS Newswire / February 26, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company focused on rebalancing inflammation... ► Artikel lesen | |
| 29.01. | REVELATION BIOSCIENCES, INC. - 8-K, Current Report | - | SEC Filings | ||
| 26.01. | Revelation Biosciences kündigt Reverse-Split im Verhältnis 1:4 an | 3 | Investing.com Deutsch | ||
| 26.01. | Revelation Biosciences to implement 1-for-4 reverse stock split | 3 | Investing.com | ||
| 26.01. | Revelation Biosciences, Inc.: Revelation Biosciences Inc. Announces 1-for-4 Reverse Stock Split Effective January 28, 2026 | 709 | ACCESS Newswire | SAN DIEGO, CALIFORNIA / ACCESS Newswire / January 26, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), announced today that, on January 28, 2026, the Company will implement... ► Artikel lesen | |
| 23.01. | Revelation Biosciences sichert sich Kapital durch Ausübungsvereinbarung für Optionsscheine | 3 | Investing.com Deutsch | ||
| 23.01. | Revelation Biosciences announces warrant exercise agreement | 1 | Investing.com | ||
| 23.01. | Revelation Biosciences, Inc.: Revelation Biosciences Inc. Announces Exercise of Warrants for $11 Million in Gross Proceeds | 410 | ACCESS Newswire | SAN DIEGO, CA / ACCESS Newswire / January 23, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company focused on rebalancing inflammation... ► Artikel lesen | |
| 23.01. | Why Did Revelation Biosciences (REVB) Stock Jump Over 25% After-Hours? | 11 | Benzinga.com | ||
| 22.01. | REVELATION BIOSCIENCES, INC. - 8-K, Current Report | 2 | SEC Filings | ||
| 21.01. | Revelation Biosciences, Inc.: Revelation Biosciences Reaches Agreement with FDA on Gemini Approval Pathway for AKI | 369 | ACCESS Newswire | - Single Phase 2/3 Adaptive Study Design -- Clinically Relevant, Objective Composite Endpoint - SAN DIEGO, CA / ACCESS Newswire / January 21, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company"... ► Artikel lesen | |
| 14.01. | Revelation Biosciences, Inc.: Revelation Biosciences Inc. to Present at The International Conference on Advances in Critical Care Nephrology | 359 | ACCESS Newswire | - Presentation to Include Additional Positive Data from the Recently Completed PRIME Clinical Study - SAN DIEGO, CA / ACCESS Newswire / January 14, 2026 / Revelation Biosciences Inc. (NASDAQ:REVB) (the... ► Artikel lesen |
1 2 Weiter >>
38 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ADMA BIOLOGICS | 11,010 | +2,42 % | Does ADMA Biologics' Growth Story Outweigh Short-Seller Concerns? | ||
| KAILERA THERAPEUTICS | 26,010 | 0,00 % | Heißes Adipositas-IPO: Kailera will es mit den Großen aufnehmen | Der wachstumsstarke Markt für Appetitzügler ist heiß umkämpft. Immer mehr Player streben in den Markt, um sich mittel- bis langfristig ein Stück vom milliardenschweren Kuchen abzuschneiden. Auch Kailera... ► Artikel lesen | |
| ALAMAR BIOSCIENCES | 22,460 | 0,00 % | Alamar Biosciences Prices Upsized IPO At $17/shr; Raises $191.3 Mln | WASHINGTON (dpa-AFX) - Alamar Biosciences, Inc. Common Stock (ALMR) on Friday announced the pricing of its upsized initial public offering of 11.25 million shares of stock at $17 per share.The... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 342,50 | +6,72 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Announces FDA Acceptance of New Drug Application for Ulixacaltamide HCl in Patients with Essential Tremor | FDA assigned PDUFA target action date of January 29, 2027 No advisory committee meeting expected BOSTON, April 14, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully... ► Artikel lesen | |
| QIAGEN | 35,350 | +1,00 % | BARCLAYS stuft QIAGEN NV auf 'Equal Weight' | LONDON (dpa-AFX Analyser) - Die britische Investmentbank Barclays hat das Kursziel für Qiagen von 58 auf 44 Dollar gesenkt, aber die Aktie von "Overweight" auf "Equal Weight" abgestuft. Eine Übernahme... ► Artikel lesen | |
| COGENT BIOSCIENCES | 37,250 | +2,93 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Poster Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2026 | ||
| TREVI THERAPEUTICS | 15,210 | +4,61 % | Netflix, Trevi Therapeutics And Other Big Stocks Moving Lower In Friday's Pre-Market Session | ||
| BIONTECH | 87,55 | +0,11 % | BioNTech-Wirkstoff BNT323 zeigt Wirkung bei Gebärmutterkrebs | BioNTech hat positive Daten aus einer Phase-2-Studie mit dem Antikörper-Wirkstoff-Konjugat Trastuzumab Pamirtecan (BNT323/DB-1303) veröffentlicht. In einer Kohorte mit stark vorbehandelten Patientinnen... ► Artikel lesen | |
| CG ONCOLOGY | 73,44 | +10,67 % | CG Oncology-Aktie erreicht Rekordhoch von 72,29 US-Dollar | ||
| SUMMIT THERAPEUTICS | 25,140 | +2,95 % | UBS reiterates Buy on Summit Therapeutics stock ahead of trial data | ||
| EVOTEC | 5,640 | +1,26 % | Aktien KW 15 Trump hält die Börsen im Griff. Wacklige Waffenruhe bringt Erholung, aber… News. Mutares. Evotec. TKMS. technotrans. HENSOLDT. Renk. Circus. Albis Leasing. Rheinmetall | Aktien - Erholungsaufatmer nach Waffenstillstand. Mit apokalyptischen Drohungen malte Trump die "Steinzeit" für den Iran an die Wand. Unter Vermittlung Pakistans - auch Chinas? - gab es kurz vorher... ► Artikel lesen | |
| IMMUNOVANT | 29,300 | +7,13 % | Immunovant Inc.: Immunovant Announces Phase 3 Study Results for Batoclimab in Thyroid Eye Disease (TED) | Phase 3 studies of batoclimab in thyroid eye disease (TED) each failed to meet their primary endpoint; safety results were consistent with previous findingsPatients in the TED studies demonstrated... ► Artikel lesen | |
| CABALETTA BIO | 3,440 | -2,27 % | Cellares' Cell Shuttle used in first patient infusions of Cabaletta Bio CAR T therapy | ||
| ERASCA | 18,995 | +4,20 % | Jefferies reiterates Erasca stock Buy rating on rival trial data | ||
| MOONLAKE IMMUNOTHERAPEUTICS | 18,340 | +3,06 % | H.C. Wainwright reiterates Moonlake stock rating on HS potential |
Das Unternehmen REVELATION BIOSCIENCES INC kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von -0,090 (-7,50 %) liegt der Kurs bei 1,110 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu REVELATION BIOSCIENCES INC finden Sie auf Wallstreet Online.